Afelimomab - Another therapeutic option in sepsis therapy?

Critical Care Medicine

Volumn 32, Issue 11, 2004, Pages 2343-2344

  Grass, Guido ^a   Neugebauer, Edmund Alwin Martin ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Afelimomab; Clinical trial; Interleukin 6; Sepsis; Tumor necrosis factor

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

ANTIBODIES, MONOCLONAL; CRITICAL CARE; EVIDENCE-BASED MEDICINE; HUMANS; INTERLEUKIN-6; PATIENT SELECTION; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 8544245713     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000146134.86536.2F     Document Type: Editorial

References (15)

1. Bernard GR, Vincent JL, Laterre PF, et al: Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. N Engl J Med 2001; 344:699-709
2. Minneci PC, Deans KJ, Banks SM, et al: Metaanalysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141:47-56
3. Rivers E, Nguyen B, Havstad S, et al: Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. TV Engl J Med 2001; 345:1368-1377
4. Vincent JL. Evidence-based medicine in the ICU: Important advances and limitations, Chest 2004; 126:592-600
5. 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182
6. Ely EW, Laterre PF, Angus DC, et al: PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
7. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-327
8. Dhainaut JF, Vincent JL, Richard C, et al: CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-1469
9. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
10. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24:1431-1440
11. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-933
12. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742
13. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769
14. Steinbrook R: Public registration of clinical trials. TV Engl J Med 2004; 351:315-317
15. MacArthur RD, Miller M, Albertson T, et al: Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS trial. Clin Infect Dis 2004; 38:284-288